Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 5Phase 3 2Phase EARLY_PHASE1 1

Status

Active not recruiting 2Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Colorectal Neoplasms 35Glioblastoma 24Carcinoma, Non-Small-Cell Lung 21Ovarian Neoplasms 14Carcinoma, Hepatocellular 14Brain Neoplasms 14Carcinoma, Renal Cell 13Pancreatic Neoplasms 12Neoplasms 10Neoplasm Metastasis 10Glioma 10Breast Neoplasms 10Colonic Neoplasms 8Astrocytoma 8Melanoma 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Liver Neoplasms 6Gliosarcoma 6Endometrial Neoplasms 6Stomach Neoplasms 5Lung Neoplasms 5Fallopian Tube Neoplasms 5Colorectal Cancer Metastatic 5Advanced Solid Tumors 5Squamous Cell Carcinoma of Head and Neck 4Prostatic Neoplasms 4Oligodendroglioma 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3

Interventions

Capecitabine 6Bevacizumab 5trifluridine tipiracil drug combination 3Cetuximab 3Oxaliplatin 2sintilimab 1monoclonal antibody YYB-101 1aflibercept 1Vemurafenib 1Nivolumab 1LY-2157299 1Irinotecan 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Colorectal Cancer Metastatic × Bevacizumab × Clear all
NCT04564898 2026-05-20

TriComB

Gruppo Oncologico del Nord-Ovest

Phase 1/2 Active not recruiting
48 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

NCT05589597 2025-08-22

AUDREY

Enterome

Phase 1/2 Terminated
25 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

NCT07012954 2025-06-24

ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

Sun Yat-sen University

Phase 1/2 Recruiting
64 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

NCT04940546 2024-12-03

Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients

Sun Yat-sen University

Phase 1/2 Active not recruiting
36 enrolled
Gastrointestinal

Colorectal Cancer Metastatic

NCT03439462 2024-01-02

Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer

Aadi Bioscience, Inc.

Phase 1/2 Completed
60 enrolled 14 charts
Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡